---
title: REVIER Therapeutics
date: 2026-08-25T08:59:39Z
modified: 2026-08-25T08:28:18Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/revier-therapeutics/"
type: portfolio
status: publish
excerpt: ""
wpid: 133134
language:
  - English
post_translations:
  - pll_6a8c6b66675c4
sectors:
  - Pharmaceuticals
focus_areas:
  - Cardiology
  - Infectious diseases
  - Metabolic Diseases
  - Neurology
timestamp: 2026-08-25T08:28:18Z
tags:
  - English
  - pll_6a8c6b66675c4
  - Pharmaceuticals
  - Cardiology
  - Infectious diseases
  - Metabolic Diseases
  - Neurology
---

## Beschreibungstext

Revier has established the first therapeutic approach to selectively target Class IIa HDACs to treat cardiometabolic diseases. Our orally available small molecules are designed to inhibit the pathogenic enzymatic activity while preserving healthy biological function and avoiding canonical HDAC inhibition. We are advancing a pipeline of novel disease modulators starting with heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD) as our initial indications. Our goal is to define a new class of treatments that directly improve cardiometabolic health and provide life-saving, long-term benefits for patients with related diseases.

## Unternehmenswebsite

> [Home](https://revier.bio/)